



# Efexor<sup>®</sup> XR

## (Venlafaxine hydrochloride) Extended-Release Capsules

### 1. NAME OF THE MEDICINAL PRODUCT

Efexor<sup>®</sup> XR


### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Venlafaxine (INN)

#### Chemical Name

(R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[α-[(dimethylamino)methyl]-p-methoxybenzyl] cyclohexanol hydrochloride

#### Structure



#### Molecular Formula

C<sub>17</sub>H<sub>27</sub>NO<sub>2</sub>HCl

#### Molecular Weight

313.87

#### Physical Characteristics

Venlafaxine Hydrochloride is a white to off-white crystalline solid.

Solubility in water: 572 mg/mL (adjusted to ionic strength of 0.2 M with sodium chloride)

Solubility in octanol: water: (0.2 M sodium chloride) partition coefficient = 0.43



### Pharmacological/Therapeutic Class

Serotonin and norepinephrine reuptake inhibitor (SNRI)

Antidepressant<sup>1,2</sup>

Anxiolytic

ATC code: NO6A X16

Capsules contain 75 mg and 150 mg venlafaxine (as hydrochloride).

### **3. PHARMACEUTICAL FORM**

Extended-release capsules for oral administration

### **4. CLINICAL PARTICULARS**

#### **4.1. THERAPEUTIC INDICATIONS**

The following are representative indications.

- Treatment of depression, including depression with associated anxiety
- For prevention of relapse and prevention of recurrence of depression
- Treatment of anxiety or generalized anxiety disorder, including long-term treatment
- Treatment of social anxiety disorder, including long-term treatment
- Treatment of panic disorder, including long-term treatment

#### **4.2. POSOLOGY AND METHOD OF ADMINISTRATION**

The following are representative dosage recommendations.

It is recommended that venlafaxine extended-release capsules be taken with food, at approximately the same time each day. Capsules must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved, or it may be administered by carefully opening the capsule and sprinkling the entire contents on a spoonful of applesauce.<sup>3</sup> This drug/food mixture should be swallowed immediately without chewing and should be followed with a glass of water to ensure complete swallowing of the pellets.

With the exception of patients with social anxiety disorder (SAD) (see below), patients not responding to the 75 mg/day dose may benefit from dose increases in increments of up to 75 mg/day to a maximum of 225 mg/day. Extended-release venlafaxine dosage increases can be made at intervals of 2 weeks or more, but not less than 4 days.



Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine extended-release capsules at the nearest equivalent daily dosage. For example, venlafaxine immediate-release tablets 37.5 mg twice daily may be switched to venlafaxine extended-release capsules 75 mg once daily. Individual dosage adjustments may be necessary.

### Major Depressive Disorder

The recommended starting dose of venlafaxine extended-release capsules is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases to a maximum of 225 mg/day.<sup>4</sup>

While the recommended dose of venlafaxine immediate-release tablets in moderately depressed patients is up to 225 mg/day more severely depressed patients in one study responded to a mean dose of 350 mg/day (range of 150 to 375 mg/day).<sup>5</sup>

### Generalized Anxiety Disorder

The recommended starting dose of venlafaxine extended-release capsules is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases to a maximum of 225 mg/day.

### Social Anxiety Disorder

The recommended dose of venlafaxine extended-release capsules is 75 mg given once daily. There is no evidence that higher doses confer any additional benefit.

### Panic Disorder

It is recommended that a dose of 37.5 mg/day of venlafaxine extended-release capsules be used for 7 days. The dose should then be increased to 75 mg/day. Patients not responding to the 75 mg/day dose may benefit from dose increases to a maximum of 225 mg/day.

### Discontinuing Venlafaxine

Gradual dose tapering is recommended when discontinuing venlafaxine therapy (see [sections 4.4. Special warnings and precautions for use](#) and [4.8. Undesirable effects](#)). In clinical trials with venlafaxine extended-release capsules, tapering was achieved by reducing the daily dose by 75 mg at 1-week intervals. However, the time period required for tapering and the amount of dose reduction may depend on the dose, duration of therapy, and the individual patient. In some patients, discontinuation may need to occur very gradually over periods of months or longer.<sup>219</sup>

### Use in Patients with Renal Impairment

The total daily dose of venlafaxine should be reduced by 25% to 50% in patients with renal impairment with a glomerular filtration rate (GFR) of 10 to 70 mL/min.<sup>6</sup>

The total daily dose of venlafaxine should be reduced by 50% in hemodialysis patients.



Because of individual variability in clearance in these patients, individualization of dosage may be desirable.

#### Use in Patients with Hepatic Impairment

The total daily dose of venlafaxine should be reduced by 50% in patients with mild to moderate hepatic impairment.<sup>7,8</sup> Reductions of more than 50% may be appropriate for some patients.

Because of individual variability in clearance in these patients, individualization of dosage may be desirable.

#### Use in Children and Adolescents

There is insufficient experience with the use of venlafaxine in patients younger than 18 years of age (see [sections 4.4 Special warnings and precautions for use](#) and [4.8 Undesirable effects](#)).

#### Use in Elderly Patients

No specific dose adjustments of venlafaxine are recommended based on patient age.<sup>9,10</sup>

### **4.3. CONTRAINDICATIONS**

Hypersensitivity to venlafaxine or any excipients in the formulation.

Concomitant use of venlafaxine and any monoamine oxidase inhibitor (MAOI).<sup>11,12,13,14,15,16</sup> Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an MAOI; a shorter interval may be justified in the case of a reversible MAOI<sup>17</sup> (see prescribing information of the reversible MAOI). Venlafaxine must be discontinued for at least 7 days before starting treatment with any MAOI (see [section 4.5. Interaction with other medicinal products and other forms of interaction](#)).

### **4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

#### Suicide/Suicidal Thoughts or Clinical Worsening

All patients treated with venlafaxine should be monitored appropriately and observed closely for clinical worsening and suicidality. Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially when initiating therapy or during any change in dose or dosage regimen.<sup>18,19,20,21</sup> The risk of suicide attempt must be considered, especially in patients with depression, and the smallest quantity of drug, consistent with good patient management, should be provided to reduce the risk of overdose (see also [section 4.8. Undesirable effects](#)).

Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are strong predictors of suicide. Pooled analyses of short-term placebo-controlled trials of antidepressant medicines (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these medicines increase the risk of suicidality in children, adolescents, and young adults (ages 18-24 years) with major depression and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults older than 24 years of age; there was a reduction in the risk of suicidality with antidepressants compared to placebo in adults age 65 years and older.<sup>22</sup>



### Aggression

Aggression may occur in some patients who have received antidepressants, including venlafaxine treatment, dose reduction, or discontinuation.<sup>37</sup> As with other antidepressants, venlafaxine should be used cautiously in patients with a history of aggression.

### Discontinuation

Discontinuation effects are well known to occur with antidepressants, and sometimes these effects can be protracted and severe (see section **4.8. Undesirable effects**). Suicide/suicidal thoughts and aggression have been observed in patients during changes in venlafaxine dosing regimen, including during discontinuation (see above in section **4.4. - Suicide/Suicidal Thoughts or Clinical Worsening and Aggression**). It is therefore recommended that the dosage of venlafaxine be tapered gradually and individually and the patients be closely monitored during discontinuation (see section **4.2. Posology and method of administration**).<sup>49,142</sup> In some patients, discontinuation could take months or longer.<sup>219</sup>

### Sexual Dysfunction

Serotonin-norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section **4.8. Undesirable effects**). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SNRIs.<sup>220</sup>

### Bone Fractures

Epidemiological studies show an increased risk of bone fractures in patients receiving serotonin reuptake inhibitors (SRIs) including venlafaxine. The mechanism leading to this risk is not fully understood.<sup>23</sup>

### Use in Children and Adolescents

Efficacy in patients younger than 18 years of age has not been established.

Regular measurement of weight and blood pressure is recommended if venlafaxine is used in children and adolescents. Discontinuation of venlafaxine treatment should be considered in children and adolescents who experience a sustained increase in blood pressure. Measurement of serum cholesterol levels should be considered during long-term treatment of children and adolescents (see **sections 4.2. Posology and method of administration** and **4.8. Undesirable effects**). Safety in children younger than 6 years of age has not been evaluated.

### NMS-like Reactions

As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition or NMS like reactions may occur with venlafaxine treatment, particularly with concomitant use of other serotonergic drugs including SSRIs, SNRIs, amphetamines,<sup>216</sup> and triptans, **opioids**<sup>221</sup> (e.g., fentanyl, dextromethorphan, tramadol, tapentadol, meperidine, methadone, pentazocine),<sup>211</sup> with drugs that impair metabolism of serotonin including MAOIs, e.g., methylene blue, or with antipsychotics or other dopamine antagonists.<sup>24,25,26</sup> Symptoms of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g.,



nausea, vomiting, and diarrhea).<sup>25</sup> Serotonin syndrome, in its most severe form, can resemble NMS, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes (see section **4.5. Interaction with other medicinal products and other forms of interaction**).

If concomitant treatment with venlafaxine and other agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.

The concomitant use of venlafaxine with serotonin precursors such as tryptophan supplements is not recommended.

#### Angle Closure Glaucoma

Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised intra-ocular pressure or patients at risk for acute narrow angle glaucoma (angle closure glaucoma) be closely monitored.<sup>27,28</sup>

#### Cardiovascular System

Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, it should be used with caution in these patients.<sup>29</sup>

Dose-related increases in blood pressure have been reported in some patients treated with venlafaxine.<sup>30</sup> Cases of elevated blood pressure requiring immediate treatment have been reported in post-marketing experience.<sup>31</sup> Measurement of blood pressure is recommended for patients receiving venlafaxine. Pre-existing hypertension should be controlled before treatment with venlafaxine.<sup>31</sup> Caution should be exercised in patients whose underlying conditions might be compromised by increases in blood pressure.

Increases in heart rate can occur, particularly with higher doses.<sup>32</sup> Caution should be exercised in patients whose underlying conditions might be compromised by increases in heart rate.

Cases of QTc prolongation, *Torsade de Pointes* (TdP), ventricular tachycardia, and sudden death have been reported during the post-marketing use of venlafaxine. The majority of reports occurred in association with overdose or in patients with other risk factors for QTc prolongation/TdP. Therefore, venlafaxine should be used with caution in patients with risk factors for QTc prolongation.<sup>212</sup>

#### Convulsions

Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be introduced with caution in patients with a history of convulsions.<sup>29,33</sup>

#### Mania/Hypomania

Mania/hypomania may occur in a small proportion of patients with mood disorders who have received antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used cautiously in patients with a history or family history of bipolar disorder.<sup>34,35,36</sup>



### Hyponatremia

Cases of hyponatremia and/or the syndrome of inappropriate antidiuretic hormone (SIADH) secretion may occur with venlafaxine, usually in volume-depleted or dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise volume depleted may be at greater risk for this event.<sup>38,39,40</sup>

### Bleeding

Drugs that inhibit serotonin uptake may lead to abnormalities of platelet aggregation.<sup>41,42,43,44</sup> There have been reports of bleeding abnormalities with venlafaxine ranging from skin and mucous membrane bleeding and gastrointestinal hemorrhage<sup>45</sup> to life-threatening hemorrhage.<sup>46,47,48,49,211</sup> As with other SRIs, venlafaxine should be used cautiously in patients predisposed to bleeding, including patients on anticoagulants and platelet inhibitors.<sup>50</sup>

### Weight Loss

The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Co-administration of venlafaxine hydrochloride and weight loss agents is not recommended. Venlafaxine hydrochloride is not indicated for weight loss, alone or in combination with other products.<sup>51</sup>

### Serum Cholesterol

Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled clinical trials. Measurement of serum cholesterol levels should be considered during long-term treatment.<sup>52</sup>

### Abuse and Dependence

Clinical studies did not show evidence of drug-seeking behavior, development of tolerance, or dose escalation over time.<sup>29,53,54</sup>

*In vitro* studies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phencyclidine (PCP), or N-methyl-D-aspartic acid (NMDA) receptors.<sup>1,55</sup> Venlafaxine was not found to have any significant central nervous system (CNS) stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability.<sup>56</sup> In a self-administration study, rhesus monkeys have been shown to self-administer venlafaxine intravenously.<sup>57</sup>

## **4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION**

### Monoamine Oxidase Inhibitors

Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to initiation of an MAOI<sup>11,12,13,14,15,16</sup> (see section **4.3. Contraindications**). These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, and hyperthermia with features resembling NMS, seizures, and death.



### CNS-Active Drugs

The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination with other CNS-active drugs.

### Serotonin Syndrome

As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system including triptans, SSRIs, other SNRIs, amphetamines,<sup>216</sup> lithium, sibutramine, **opioids<sup>221</sup>** (e.g., fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine)<sup>211</sup> or St. John's wort (*Hypericum perforatum*),<sup>58</sup> with drugs that impair the metabolism of serotonin such as MAOIs, including linezolid (an antibiotic, which is a reversible non-selective MAOI) and methylene blue; or with serotonin precursors such as tryptophan supplements (see sections **4.3. Contraindications** and **4.4. Special warnings and precautions for use**).<sup>26</sup>

If concomitant treatment with venlafaxine and an SSRI, an SNRI, or a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.<sup>25</sup>

The concomitant use of venlafaxine with serotonin precursors such as tryptophan supplements is not recommended (see section **4.4. Special warnings and precautions for use**).

### Drugs that Prolong QT Interval

The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with concomitant use of other drugs, which prolong the QTc interval (e.g., some antipsychotics and antibiotics)<sup>212</sup> (see section **4.4. Special warnings and precautions for use**).

### Indinavir

A pharmacokinetic study with indinavir has shown a 28% decrease in area under the concentration versus time curve (AUC) and a 36% decrease in  $C_{max}$  for indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine (ODV). The clinical significance of this interaction is unknown.

### Ethanol

Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by ethanol.<sup>59</sup> However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking venlafaxine.

### Haloperidol

A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70% increase in AUC, an 88% increase in  $C_{max}$ , but no change in half-life.<sup>60</sup> This should be taken into account in patients treated with haloperidol and venlafaxine concomitantly.



### Cimetidine

At steady state, cimetidine has been shown to inhibit first-pass metabolism of venlafaxine; However, cimetidine had no effect on the pharmacokinetics of ODV. The overall pharmacological activity of venlafaxine plus ODV is expected to increase only slightly in most patients.<sup>61</sup> In the elderly and in patients with hepatic dysfunction, this interaction may be more pronounced.

### Imipramine

Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. However, desipramine AUC,  $C_{max}$ , and  $C_{min}$  increased by about 35% in the presence of venlafaxine. There was an increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold. Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.<sup>62</sup> This should be taken into account in patients treated with imipramine and venlafaxine concomitantly.

### Ketoconazole

A pharmacokinetic study with ketoconazole in extensive metabolizers (EM) and poor metabolizers (PM) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and ODV in subjects, following administration of ketoconazole. Venlafaxine  $C_{max}$  increased by 26% in EM subjects and 48% in PM subjects.  $C_{max}$  values for ODV increased by 14% and 29% in EM and PM subjects, respectively. Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects. AUC values for ODV increased by 23% and 33% in EM and PM subjects, respectively<sup>63,64</sup> (see **section 4.5. Interaction with other medicinal products and other forms of interaction**; Potential for Other Drugs to Affect Venlafaxine).

### Metoprolol

Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to healthy volunteers in a pharmacokinetic interaction study for both drugs resulted in increase in plasma concentrations of metoprolol by approximately 30%-40% without altering the plasma concentrations of its active metabolite,  $\alpha$ -hydroxymetoprolol. Venlafaxine appeared to reduce the blood pressure lowering effect of metoprolol in this study of healthy volunteers. The clinical relevance of this finding in hypertensive patients is unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, ODV.<sup>65</sup> Caution should be exercised with co-administration of venlafaxine and metoprolol.

### Risperidone

Venlafaxine increased risperidone AUC by 32% but did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).<sup>66</sup> The clinical significance of this interaction is unknown.

### Diazepam

Diazepam does not appear to affect the pharmacokinetics of either venlafaxine or ODV. Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active metabolite, desmethyldiazepam.<sup>67</sup>



### Lithium

The steady-state pharmacokinetics of venlafaxine and ODV are not affected when lithium is co-administered. Venlafaxine has no effect on the pharmacokinetics of lithium<sup>68</sup> (see also subheading above, [CNS-Active Drugs](#)).

### Drugs Highly Bound to Plasma Proteins

Venlafaxine is not highly bound to plasma proteins (27% bound); therefore, administration of venlafaxine to a patient taking another drug that is highly protein bound is not expected to cause increased free concentrations of the other drug.<sup>69,70</sup>

### Drugs Metabolized by Cytochrome P450 Isoenzymes

Studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6.<sup>71,72</sup> Venlafaxine did not inhibit CYP3A4, CYP1A2, and CYP2C9 *in vitro*.<sup>72</sup> This was confirmed by *in vivo* studies with the following drugs: alprazolam<sup>73</sup> (CYP3A4), caffeine<sup>74</sup> (CYP1A2), carbamazepine<sup>75</sup> (CYP3A4), diazepam,<sup>67</sup> (CYP3A4 and CYP2C19), and tolbutamide (CYP2C9).<sup>72,76</sup>

### Potential for Other Drugs to Affect Venlafaxine

The metabolic pathways for venlafaxine include CYP2D6 and CYP3A4. Venlafaxine is primarily metabolized to its active metabolite, ODV, by the cytochrome P450 enzyme, CYP2D6. CYP3A4 is a minor pathway relative to CYP2D6 in the metabolism of venlafaxine.<sup>77</sup>

### CYP2D6 Inhibitors

Concomitant use of CYP2D6 inhibitors and venlafaxine may reduce the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of ODV. As venlafaxine and ODV are both pharmacologically active, no dosage adjustment is required when venlafaxine is co-administered with a CYP2D6 inhibitor.<sup>2,78</sup>

### CYP3A4 Inhibitors

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase the levels of venlafaxine and ODV (see section **4.5. Interaction with other medicinal products and other forms of interaction**).<sup>64,79</sup> Therefore, caution is advised when combining venlafaxine with a CYP3A4 inhibitor.

### CYP2D6 and CYP3A4 Inhibitors

The concomitant use of venlafaxine with drug treatment(s) that potentially inhibits both CYP2D6 and CYP3A4, the primary metabolizing enzymes for venlafaxine, has not been studied. However, this concomitant use would be expected to increase venlafaxine plasma concentrations. Therefore, caution is advised when combining venlafaxine with any agent(s) that produces simultaneous inhibition of these two enzyme systems.<sup>2,64,78,80</sup>



### Electroconvulsive Therapy

There are no clinical data establishing the benefit of electroconvulsive therapy combined with venlafaxine treatment.

### Drug-Laboratory Test Interactions

False-positive urine immunoassay screening tests for PCP and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests.

False-positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.<sup>81</sup>

## **4.6. FERTILITY, PREGNANCY AND LACTATION**

The safety of venlafaxine in human pregnancy has not been established. Venlafaxine must be administered to pregnant women only if the expected benefits outweigh the possible risks. If venlafaxine is used until or shortly before birth, discontinuation effects in the newborn should be considered.<sup>82</sup> Some neonates exposed to venlafaxine late in the third trimester have developed complications requiring tube feeding, respiratory support, or prolonged hospitalization. Such complications can arise immediately upon delivery.<sup>83,84</sup>

When venlafaxine was administered orally to pregnant rats throughout gestation and lactation, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation, when dosing began during pregnancy and continued until weaning.<sup>85</sup> The cause of these deaths is not known. These effects occurred at 10 times the human daily dose (on a mg/kg basis) or 2.5 times (on a mg/m<sup>2</sup> basis) the human daily dose of 375 mg of venlafaxine. The no-effect dose for rat pup mortality was 1.4 times the human dose, on a mg/kg basis, or 0.25 times the human dose, on a mg/m<sup>2</sup> basis.

A prospective longitudinal study of 201 women with a history of major depression who were euthymic at the beginning of pregnancy showed that women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.<sup>217</sup>

Exposure to SNRIs in mid to late pregnancy may increase the risk for preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum haemorrhage.<sup>217</sup>

Venlafaxine and ODV are excreted in human milk; therefore, a decision should be made whether to breast-feed or to discontinue venlafaxine.<sup>86</sup>

## **4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

Venlafaxine did not affect psychomotor, cognitive, or complex behavior performance in healthy volunteers. However, any psychoactive drug may impair judgment, thinking, and motor skills. Therefore, patients should be cautioned about their ability to drive or operate hazardous machinery.<sup>87,88,89</sup>



#### 4.8. UNDESIRABLE EFFECTS

##### Adverse Drug Reaction Table<sup>214</sup>

The following table lists adverse drug reactions (ADRs) within each standard System Organ Class (SOC) by decreasing order of medical seriousness.

System Organ Class	Adverse Drug Reactions
Blood and lymphatic system disorders	Agranulocytosis <sup>*101,102</sup> , Aplastic anaemia <sup>*101,103</sup> , Pancytopenia <sup>*101,103</sup> , Neutropenia <sup>*101,104</sup> , Thrombocytopenia <sup>*100</sup>
Immune system disorders	Anaphylactic reaction*
Endocrine disorders	Inappropriate antidiuretic hormone secretion <sup>*110</sup> , Blood prolactin increased <sup>*111,112</sup>
Metabolism and nutrition disorders	Hyponatraemia*, Decreased appetite
Psychiatric disorders	Delirium <sup>*123,124</sup> , Confusional state <sup>*116</sup> , Mania, Hypomania, Depersonalisation <sup>*117</sup> , Hallucination, Insomnia, Abnormal dreams, Nervousness, Libido decreased, Agitation <sup>*118,119</sup> , Anorgasmia, Abnormal orgasm, Bruxism <sup>*95</sup> , Apathy
Nervous system disorders	Neuroleptic malignant syndrome*, Serotonin syndrome <sup>*122</sup> , Akathisia <sup>*121</sup> , Syncope, Convulsion, Headache <sup>*115</sup> , Dizziness, Sedation, Tremor, Paraesthesia, Dysgeusia, Myoclonus, Balance disorder <sup>*120</sup> , Coordination abnormal <sup>*120</sup> , Dyskinesia <sup>*125,126</sup> , Dystonia <sup>*125,126</sup> , Tardive dyskinesia <sup>*127</sup>
Eye disorders	Angle closure glaucoma <sup>*28</sup> , Visual impairment, Accommodation disorder, Mydriasis
Ear and labyrinth disorders	Tinnitus <sup>*138,139</sup>
Cardiac disorders	Stress cardiomyopathy (takotsubo cardiomyopathy) <sup>*218</sup> , <i>torsade de pointes</i> <sup>*94</sup> , Ventricular tachycardia <sup>*94</sup> , Ventricular fibrillation <sup>*94</sup> , Electrocardiogram QT prolonged <sup>*94</sup> , Tachycardia, Palpitations <sup>*93</sup>
Vascular disorders	Hypertension, Orthostatic hypotension, Hypotension*, Hot flush
Respiratory, thoracic and mediastinal disorders	Dyspnoea <sup>*210</sup> , Interstitial lung disease <sup>*213</sup> , Pulmonary eosinophilia <sup>*128,129</sup> , Yawning
Gastrointestinal disorders	Gastrointestinal haemorrhage <sup>*45</sup> , Pancreatitis <sup>*98,99</sup> , Diarrhoea <sup>*96,97</sup> , Vomiting, Nausea, Dry mouth, Constipation
Hepatobiliary disorders	Hepatitis <sup>*106,107,108,109</sup> , Liver function test abnormal*
Skin and subcutaneous tissue disorders	Stevens-Johnson syndrome <sup>*133</sup> , Toxic epidermal necrosis <sup>*137</sup> , Angioedema <sup>*92</sup> , Erythema multiforme <sup>*132</sup> , Rash, Hyperhidrosis*, Pruritus <sup>*134,135</sup> , Night sweats <sup>*130</sup> , Urticaria <sup>*136</sup> , Alopecia <sup>*131</sup> , Ecchymosis, Photosensitivity reaction
Musculoskeletal and connective tissue disorders	Rhabdomyolysis <sup>*113,114</sup> , Hypertonia
Renal and urinary disorders	Urinary hesitation, Urinary retention, Urinary incontinence <sup>*141</sup> , Pollakiuria <sup>*141</sup>
Reproductive system and breast disorders	Ejaculation disorder <sup>*220</sup> , Erectile dysfunction <sup>*220</sup> , Metrorrhagia <sup>*140</sup> , Menorrhagia <sup>*140</sup>
General disorders and administration site conditions	Fatigue, Asthenia, Chills <sup>*91</sup> , Mucosal haemorrhage*
Investigations	Bleeding time prolonged*, Weight decreased, Weight increased, Blood cholesterol increased <sup>*105</sup>



System Organ Class	Adverse Drug Reactions
Injury, poisoning and procedural complications	Bone fracture <sup>23</sup>

\*ADR identified post-marketing.

### Discontinuation Effects

The following symptoms have been reported in association with abrupt discontinuation or dose reduction, or tapering of treatment<sup>49,142</sup>: hypomania, anxiety, agitation, nervousness, confusion, insomnia or other sleep disturbances, fatigue, somnolence, paresthesia, dizziness, convulsion,<sup>143</sup> vertigo, headache, flu-like symptoms,<sup>144</sup> tinnitus,<sup>145</sup> impaired coordination and balance,<sup>120</sup> tremor,<sup>146</sup> sweating, dry mouth, anorexia, diarrhoea, nausea, vomiting,<sup>147</sup> visual impairment, and hypertension.<sup>219</sup> In premarketing studies, the majority of discontinuation reactions were mild and resolved without treatment (see sections **4.2. Posology and method of administration** and **4.4. Special warnings and precautions for use**).<sup>148,149</sup> While these events are generally self-limiting, there have been reports of serious discontinuation symptoms, and sometimes these effects can be protracted and severe.<sup>219</sup>

### Pediatric Patients

In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children and adolescents (aged 6 to 17) was similar to that seen in adults. As with adults, decreased appetite, weight loss, increased blood pressure, and increased serum cholesterol were observed (see sections **4.4. Special warnings and precautions for use** and **4.8. Undesirable effects**).

In pediatric clinical trials, the adverse reaction suicidal ideation was observed. There were also increased reports of hostility and, especially in major depressive disorder, self-harm.<sup>150</sup>

Particularly, the following adverse reactions were observed in pediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.<sup>151</sup>

## **4.9. OVERDOSE**

In post-marketing experience, overdose with venlafaxine was reported predominantly in combination with alcohol and/or other drugs.<sup>49,152,153,154,155</sup> The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, convulsion, and vomiting.<sup>156</sup> Other events reported include electrocardiographic changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, vertigo, and death.



Published retrospective studies report that venlafaxine overdose may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants.<sup>157,158,159,160</sup> Epidemiological studies have shown that venlafaxine-treated patients have a higher burden of suicide risk factors than SSRI-treated patients.<sup>161,162,163</sup> The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdose as opposed to some characteristics of venlafaxine-treated patients is not clear. Prescriptions for venlafaxine should be written for the smallest quantity of drug consistent with good patient management, in order to reduce the risk of overdose.

### Recommended Treatment

General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must be monitored.

When there is a risk of aspiration, induction of emesis is not recommended.

Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients.

Administration of activated charcoal may also limit drug absorption.

Forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit.

No specific antidotes for venlafaxine are known.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1. PHARMACODYNAMIC PROPERTIES**

Venlafaxine and its active metabolite, ODV, are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.<sup>1,2</sup> The antidepressant activity of venlafaxine is thought to be associated with potentiation of neurotransmitter activity in the CNS.<sup>164</sup> Venlafaxine and ODV have no significant affinity for muscarinic, histaminergic, or  $\alpha_1$ -adrenergic receptors *in vitro*.<sup>1</sup> Activity at these receptors is potentially associated with various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. In preclinical rodent models, venlafaxine demonstrated activity predictive of antidepressant and anxiolytic actions, and cognitive-enhancing properties.<sup>2,165,166</sup>

#### Cardiac Electrophysiology

In a dedicated thorough QTc study in healthy subjects, venlafaxine did not prolong the QT interval to any clinically relevant extent at a dose of 450 mg/day (given as 225 mg twice a day).<sup>215</sup>

#### Venlafaxine Extended-Release Capsules

##### Depression

The efficacy of venlafaxine extended-release capsules as a treatment for depression, including depression with associated anxiety,<sup>171</sup> was established in two placebo-controlled short-term studies.<sup>172,173</sup> Populations in both trials consisted of outpatients meeting DSM-III-R or DSM-IV criteria for major depression.

The first study compared extended-release venlafaxine 75 to 150 mg/day, immediate-release venlafaxine 75 to 150 mg/day, and placebo for 12 weeks. Extended-release venlafaxine showed significant advantage over



placebo starting at Week 2 of treatment on the Hamilton Rating Scale for Depression (HAM-D) Score and HAM-D Depressed Mood Item,<sup>174</sup> at Week 3 on the Montgomery-Asberg Depression Rating Scale (MADRS) total,<sup>175</sup> and at Week 4 on the Clinical Global Impressions (CGI) Severity of Illness Scale.<sup>176</sup> All advantages were maintained through the end of treatment. Extended-release venlafaxine also showed significant advantage over immediate-release venlafaxine at Weeks 8 and 12 on the HAM-D total and CGI Severity of Illness Scale and at Week 12 for all efficacy variables.<sup>172</sup>

The second study compared treatment with extended-release venlafaxine 75 to 225 mg/day and placebo for up to 8 weeks. Sustained statistical improvement over placebo was seen beginning at Week 2 for the CGI Severity of Illness Scale, beginning at Week 4 for the HAM-D total and MADRS total, and beginning at Week 3 for the HAM-D Depressed Mood Item.<sup>173</sup>

### Generalized Anxiety Disorder

The efficacy of venlafaxine extended-release capsules as a treatment for GAD was established in two short-term (8-week), placebo-controlled, fixed-dose studies; one long-term (6-month), placebo-controlled, fixed-dose study; and one long-term (6-month), placebo-controlled, flexible-dose study in outpatients meeting DSM-IV criteria for GAD.

One short-term study evaluating extended-release venlafaxine doses of 75, 150, and 225 mg/day, and placebo showed that the 225 mg/day dose was more effective than placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score, both the HAM-A anxiety and tension items, and the CGI scale. While there was also evidence for superiority over placebo for the 75 and 150 mg/day doses, these doses were not as consistently effective as the highest dose.<sup>177</sup>

A second short-term study evaluating extended-release venlafaxine doses of 75 and 150 mg/day, and placebo showed that both doses were more effective than placebo on some of these same outcomes; however, the 75 mg/day dose was more consistently effective than the 150 mg/day dose.<sup>178</sup> Two long-term (6-month) studies, one with extended-release venlafaxine doses of 37.5, 75, and 150 mg/day and the other evaluating doses of 75 to 225 mg/day, showed that doses of 75 mg or higher were more effective than placebo on the HAM-A total, both the HAM-A anxiety and tension items, and the CGI scale after short-term (Week 8) and long-term (Month 6) treatment.<sup>179,180,181,182</sup>

## **5.2. PHARMACOKINETIC PROPERTIES**

### Absorption

At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine.<sup>183</sup> Absolute bioavailability is 40% to 45% due to presystemic metabolism.<sup>184</sup> In single-dose studies with 25 mg to 150 mg of immediate-release venlafaxine, mean peak plasma concentrations ( $C_{max}$ ) range from 37 to 163 mg/mL respectively and are attained within 2.1 to 2.4 hours ( $t_{max}$ ).<sup>185</sup> Following the administration of venlafaxine extended-release capsules, peak plasma concentrations of venlafaxine and ODV are attained within 5.5 and 9 hours, respectively.<sup>186</sup> Following the administration of venlafaxine immediate-release, peak plasma concentrations of venlafaxine and ODV are attained in 2 and 3 hours, respectively. Venlafaxine extended-release capsules and venlafaxine immediate-release tablets are associated with a similar extent of absorption.<sup>186</sup>



### Distribution

Steady-state concentrations of both venlafaxine and ODV in plasma are attained within 3 days of multiple-dose therapy of immediate-release venlafaxine. Both show linear kinetics over a dose range of 75 to 450 mg/day when administered every 8 hours.<sup>185</sup> Venlafaxine and ODV are approximately 27% and 30% bound to human plasma proteins, respectively.<sup>69,70</sup> Since this binding is independent of respective drug concentrations up to 2,215 and 500 ng/mL, both venlafaxine and ODV have low potential for involvement in significant drug-drug interactions involving drug displacement from serum proteins. The volume of distribution for venlafaxine at steady state is  $4.4 \pm 1.9$  L/kg following intravenous administration.<sup>184</sup>

### Metabolism

Venlafaxine undergoes extensive hepatic metabolism.<sup>187</sup> *In vitro* and *in vivo* studies indicate that venlafaxine is biotransformed to its major active metabolite, ODV, by the P450 isoenzyme CYP2D6.<sup>188</sup> *In vitro*<sup>189</sup> and *in vivo*<sup>77</sup> studies indicate that venlafaxine is metabolized to a minor, less active metabolite, N-desmethylvenlafaxine,<sup>2</sup> by CYP3A4. Although the relative activity of CYP2D6 may differ among patients, related modification of the venlafaxine dosage regimen is not required.<sup>190</sup> Drug exposure (AUC) and fluctuation in plasma levels of venlafaxine and ODV were comparable following administration of equal daily doses of venlafaxine as twice daily or three times daily regimens of immediate-release venlafaxine.<sup>191</sup>

### Elimination

Venlafaxine and its metabolites are excreted primarily through the kidneys.<sup>183</sup> Approximately 87% of venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).<sup>183</sup>

### Effects of Food

Food has no significant effect on the absorption of venlafaxine or the formation of ODV.<sup>192,193</sup>

### Patients with Hepatic Impairment

The pharmacokinetic disposition of venlafaxine and ODV are significantly altered in some patients with compensated hepatic cirrhosis (moderate hepatic impairment) following oral administration of single-dose venlafaxine. In patients with hepatic impairment, mean plasma clearance of venlafaxine and ODV are reduced by approximately 30% to 33% and mean elimination half-lives are prolonged by 2-fold or more compared to normal subjects.<sup>7</sup>

In a second study, venlafaxine was administered orally and intravenously in normal subjects (n = 21), and in Child-Pugh A (n = 8) and Child-Pugh B (n = 11) subjects, mildly and moderately hepatically impaired, respectively. Oral bioavailability approximately doubled in patients with hepatic impairment compared to normal subjects. In patients with hepatic impairment, venlafaxine oral elimination half-life was approximately twice as long and oral clearance was reduced by more than half compared to normal subjects. In patients with hepatic impairment, ODV oral elimination half-life was prolonged by about 40% while oral clearance for ODV was similar to that for normal subjects. A large degree of intersubject variability was noted.<sup>8,194</sup>



### Patients with Renal Impairment

Venlafaxine and ODV elimination half-lives increase with the degree of impairment in renal function. Elimination half-life increased by approximately 1.5-fold in patients with moderate renal impairment and by approximately 2.5-fold and 3-fold in patients with end-stage renal disease.<sup>6</sup>

### Age and Gender Studies

A population pharmacokinetic analysis of 404 immediate-release venlafaxine-treated patients from two studies involving both twice daily and three times daily regimens showed that dose-normalized trough plasma levels of either venlafaxine or ODV were unaltered by age or gender differences.<sup>195,196</sup>

## **5.3. PRECLINICAL SAFETY DATA**

### Carcinogenicity

Venlafaxine was given by oral gavage to mice for 18 months at doses up to 120 mg/kg per day, which was 1.7 times the maximum recommended human dose, on a mg/m<sup>2</sup> basis.<sup>197</sup> Venlafaxine was also given to rats by oral gavage for 24 months at doses up to 120 mg/kg per day.<sup>198</sup> In rats receiving the 120 mg/kg dose, plasma concentrations of venlafaxine at necropsy were 6 times (female rats) and 1 times (male rats) the plasma concentrations of patients receiving the maximum recommended human dose. Plasma levels of ODV were lower in rats than in patients receiving the maximum recommended dose. Tumors were not increased by venlafaxine treatment in mice or rats.<sup>197,198</sup>

### Mutagenicity

Venlafaxine and ODV were not mutagenic in the Ames reverse mutation assay in *Salmonella* bacteria or the Chinese hamster ovary/hypoxanthine guanine phosphoribosyl transferase (HGPRT) mammalian cell forward gene mutation assay.<sup>199,200,201</sup> Venlafaxine was also not mutagenic or clastogenic in the *in vitro* BALB/c-3T3 mouse cell transformation assay, the sister chromatid exchange assay in cultured Chinese hamster ovary cells, or in the *in vivo* chromosomal aberration assay in rat bone marrow.<sup>201,202,203,204</sup> O-desmethylvenlafaxine was not clastogenic in the *in vitro* Chinese hamster ovary cell chromosomal aberration assay, or in the *in vivo* chromosomal aberration assay in rat bone marrow.<sup>201</sup>

### Impairment of Fertility

Reproduction and fertility studies in rats showed no effect on male or female fertility at oral doses of up to 8 times the maximum recommended human daily dose, on a mg/kg basis, or of up to 2 times, on a mg/m<sup>2</sup> basis.<sup>205</sup>

Reduced fertility was observed in a study in which both male and female rats were exposed to the major metabolite of venlafaxine (ODV). This ODV exposure was approximately 2 to 3 times that of a human venlafaxine dose of 225 mg/day.<sup>206</sup> The human relevance of this finding is unknown.<sup>207</sup>



### Teratogenicity

Venlafaxine did not cause malformations in offspring of rats or rabbits given doses up to 11 times (rat) or 12 times (rabbit) the human dose of 375 mg/day of venlafaxine on a mg/kg basis, or 2.5 times (rat)<sup>208</sup> and 4 times (rabbit)<sup>209</sup> the human dose of 375 mg/day of venlafaxine, on a mg/m<sup>2</sup> basis.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1. LIST OF EXCIPIENTS**

#### Capsule:

Venlafaxine HCl  
Microcrystalline Cellulose (PH101)  
Hypromellose 2208, 3cp  
Hypromellose 2910, 6cps  
Ethylcellulose 50 cps  
Talc  
Ink  
1 hard gelatin capsule  
Red Iron Oxide  
Yellow Iron Oxide  
Titanium Dioxide  
Gelatin

#### Ink Composition:

Shellac  
Iron Oxide  
N-Butyl, Alcohol  
Isopropyl Alcohol  
Propylene Glycol  
Ammonium Hydroxide  
Simethicone

### **6.2. INCOMPATIBILITIES**

Not applicable

### **6.3. SHELF LIFE**

Please see pack for expiry of product.

### **6.4. SPECIAL PRECAUTIONS FOR STORAGE**

Protect venlafaxine extended-release capsules from light and dispense in a light-resistant container.  
Store venlafaxine in a well-closed container.



#### 6.5. NATURE AND CONTENTS OF CONTAINER

Efexor® XR (venlafaxine) Capsules is available as 75 mg and 150 mg in the packs of 14s.

#### 6.6. SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

The extended-release formulation of venlafaxine capsules contains spheroids, which release the drug slowly into the digestive tract. The insoluble portion of these spheroids is eliminated and may be seen in stools.

**Efexor/LPD/PK-08**

**According to CDS V 35 dated; 09 June 2021; Supersedes CDS V 34 dated; 10 July 2019**

**Marketed by:**

Wyeth Pakistan Limited

*Please visit our website [www.pfizerpro.com.pk](http://www.pfizerpro.com.pk) for latest version of Product leaflet.*



## 7. REFERENCES

1. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg E. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. *Biochem Pharmacol* 1986; 35(24):4493-7.
2. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GE. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. *Drug Dev Res* 1991; 23:191-9.
3. CSR-41531, Version 1.0, Final Report: An open-label, 2-period, randomized, crossover study to evaluate the relative bioavailability of venlafaxine extended-release sprinkled over applesauce, 24-May-2002.
4. Taylor L, Entsuah AR, Aguiar L. An open-label evaluation of the long-term safety and clinical acceptability of venlafaxine extended-release capsules in depressed outpatients: final report (Protocol 0600B1-369-US). Wyeth GMR-29962, 1997.
5. Guelfi JD, White C, Hackett D, Guichoux J, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. *J Clin Psychiatry* 1995;56:450-8.
6. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. *Clin Pharmacol Ther* 1994; 56:14-21.
7. Troy S, Bulow L, Wallace D. Pharmacokinetic and statistical evaluation of the effect of hepatic disease on the disposition of venlafaxine: final report (Protocol 600A-110-US). Wyeth-Ayerst Laboratories GMR-18916, 1990
8. Justification document: Venlafaxine Hydrochloride: Rationale for revisions to label wording for dosage adjustments for patients with hepatic impairment.
9. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. *Pharmacother* 1996; 16(5):915-23.
10. Behrle JA, Malley MT, Richards L. Final report: The effects of age and gender on the pharmacokinetics, safety, and tolerability of desvenlafaxine SR administered orally to health subjects (Protocol no. 0600D3-175-US). Wyeth Research CSR-50504, 2005.
11. Data on file, Wyeth-Ayerst Laboratories. 1<sup>st</sup> Venlafaxine Periodic Safety Update Report (PSUR), 5-May-1994 to 5-May-1995.
12. Brubacher JF, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranlycypromine interaction. *Vet Human Toxicol* 1996;38(5):358-61.



13. Hodgman M, Martin T, Dean B, Krenzelok E. Severe serotonin syndrome secondary to venlafaxine and maintenance tranylcypromine therapy. *J Toxicol Clin Toxicol* 1995; 33(5):554.
14. Klysner R, Larsen JK, Sørensen P, Hyllested M, Pedersen BD. Toxic interaction of venlafaxine and isocarboxazide. *Lancet* 1995; 346:1298-9.
15. Phillips SD, Ringo P. Phenelzine and venlafaxine interaction. *Am J Psychiatry* 1995;152(9):1400-1.
16. Heisler MA, Guidry JR, Arnecke B. Serotonin syndrome induced by administration of venlafaxine and phenelzine. *Ann Pharmacother* 1996; 30:84.
17. Tiller JWG. Clinical overview on moclobemide. *Prog Neuro-Psychopharmacol Biol Psychiat* 1993; 17:703-712.
18. Justification document: Venlafaxine: Revisions to labeling language regarding possible risk of suicide.
19. Akiskal HS, Benazzi F, Perugi G, et al. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy. *Journal of Affective Disorders* 2005; 85:245-58.
20. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. *Hum Psychopharmacol Clin Exp.* 2001; 16:495-505.
21. Culpepper L, Davidson JRT, Dietrich AJ, et al. Suicidality as a Possible Side Effect of Antidepressant Treatment. *Physicians Postgraduate Press, Inc.* 2004;79-88
22. Laughren T. Memorandum – Department of Health and Human Services Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC), dated November 16, 2006.
23. 2.5 Clinical Overview Venlafaxine CDS Revision\_Bone Fracture\_2012
24. Justification Document: Venlafaxine HCL: Serotonin Syndrome/Drug interactions with CNS active drugs.
25. Boyer EW, Shannon M. The Serotonin Syndrome. *N Engl J Med* 2005; 352:1112-20.
26. 2.5 Clinical Overview. Potential Drug Interaction Between Venlafaxine and Methylene Blue.
27. Turner, ME. Increased Intraocular Pressure and Glaucoma. Data on file, Wyeth-Ayerst Laboratories, 1998.
28. Justification document: Venlafaxine Hydrochloride: Angle closure glaucoma.



29. Data on file, Wyeth-Ayerst Laboratories. Venlafaxine immediate-release NDA 20-151, 1993.
30. Thase M. Effects of Venlafaxine on Blood Pressure: A meta-analysis of original data from 3744 depressed patients. *J Clin Psychiatry* 1998; 59(10):502-8.
31. Justification document: Venlafaxine HCl: Modifications to labeling language on hypertension coincident with venlafaxine use.
32. Data on file, Justification for Heart Rate Precaution February 2000, Wyeth-Ayerst Laboratories.
33. Data on file, Wyeth-Ayerst Laboratories. Venlafaxine immediate-release NDA 20-151, Volume 1, Integrated Summary of Safety Information: Final. 155-8, 170-3. 1993.
34. Kaplan HI, Sadock BJ. Synopsis of psychiatry 6<sup>th</sup> ed. Baltimore: Williams & Wilkins; 1991. p 258.
35. Yager J, Gitlin M. Clinical manifestations of psychiatric disorders. In: Sadock BJ, Sadock VA. *Kaplan and Sadock's Comprehensive Textbook of Psychiatry*. Vol 1, 8th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005: 964-1002.
36. Benazzi F, Koukopoulos A, Akisal HS. Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). *J. Eur Psy* 2003;19:85-90.
37. Justification document: Venlafaxine Hydrochloride: Aggression with venlafaxine HCl use and with venlafaxine HCl dose reduction or discontinuation.
38. Holohan NM, Kettl PA. Syndrome of inappropriate antidiuretic hormone secretion induced by venlafaxine. Proceedings of the Annual Meeting of the American Psychiatric Association 1998; 151:86 Suppl: NR71.
39. Masood GR, Karki SD, Patterson WR. Hyponatremia with venlafaxine. *Ann Pharmacother* 1998;32(1):49-50.
40. Meynaar IA, Peeters AJ, Mulder AH, Ottervanger JP. Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine. *Neth J Med* 1997; 50(6):243-5.
41. Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. *Ann Pharmacother*. 1996;30:786-8.
42. Cooper TA, Valcour VG, Gibbons RB, et al. Spontaneous ecchymoses due to paroxetine administration. *Am J Med*. 1998;104:197-8.
43. Kohn S, Labbate LA. Venlafaxine and ecchymosis. *Can J Psychiatry* 1997; 42:91.



44. DeClerck FF, Herman AG. 5-hydroxytryptamine and platelet aggregation. *Fed Proc.* 1983;149:228-232.
45. Justification Document: Justification for a safety labeling decision for venlafaxine: Gastrointestinal hemorrhage.
46. Kohn S, Labbate LA. Venlafaxine and ecchymosis. *Can J Psychiatry* 1997;42(1):91.
47. Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. *Ann Pharmacother* 1996;30:786-8.
48. Cooper TA, Valcour VG, Gibbons RB, et al. Spontaneous ecchymoses due to paroxetine administration. *Am J Med* 1998; 104:197-198.
49. Data on file, Wyeth-Ayerst Laboratories. Spontaneous Adverse Event Reporting System.
50. Justification Document: Justification for a safety labeling decision for venlafaxine: Warfarin interaction.
51. Justification Document: Venlafaxine Hydrochloride: Recommendation Against Concomitant Use of Venlafaxine and Weight Loss Agents.
52. Justification Document: Venlafaxine hydrochloride: Increased cholesterol.
53. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. *J Clin Psychopharmacol* 1994;14(5):322-9.
54. Magni G, Hackett D. An open-label evaluation of the long-term safety and clinical acceptability of venlafaxine in depressed patients. *Clin Neuropharm* 1992;15 Suppl 1:323B.
55. Tasse R. The N-methyl-D-aspartic acid and phencyclidine receptor affinities of venlafaxine, Wy-45,233, and imipramine. Wyeth-Ayerst Laboratories GTR-18813, 1990.
56. Nader MA, Woolverton WL. Evaluation of the discriminative stimulus effects of venlafaxine, a potential antidepressant, in rhesus monkeys. *Drug Dev Res* 1992; 25:75-80.
57. Latta D. Venlafaxine: a drug dependency study on the reinforcing effect when administered by intravenous self-administration to rhesus monkeys (INA research inc. report no. LA05340, 2006). Wyeth Research. RPT-67102, 2006.
58. Mannel M. Drug interactions with St John's wort; mechanisms and clinical implications. *Drug Safety* 2004;27(11):773-97.
59. Troy SM, Turner MB, Unruh M, Parker VD, Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. *J Clin Pharmacol* 1997; 37:1073-81.



60. Kelly EA. An open-label study to evaluate the effect of venlafaxine on the pharmacokinetic disposition of haloperidol in healthy male and female volunteers. Wyeth-Ayerst Laboratories Integrated Clinical and Statistical Report: Protocol 95-059-MA, 1996.
61. Troy SM, Rudolph R, Mayersohn M, Chiang S. The influence of cimetidine on the deposition kinetics of the antidepressant venlafaxine. *J Clin Pharmacol* 1998;38:467-74.
62. Troy SM, Kitzen JM, DiLea C. An open-label study of the effect of venlafaxine on imipramine metabolism mediated by the cytochrome P-450 isoenzyme CYP2D6 in extensive metabolizers of dextromethorphan and mephenytoin: Final Report (Protocol 600-A-129-US). Wyeth-Ayerst Laboratories GMR-26709, 1996.
63. Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolizers of debrisoquine. *Eur J Clin Pharmacol*. 2003; 59: 401-6.
64. Correspondence: Email from Lindh JD dated 4/28/2006 to Nichols A.: Correction of mean AUC change.
65. Troy SM, Blackman BC, Patat A. Evaluation of the potential pharmacokinetic interaction between venlafaxine and metoprolol in healthy male volunteers (protocol 0600-A-132-SW). Wyeth Research CSR-26916, 2004.
66. Amchin J, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. *J Clin Pharmacol* 1999; 39:297-309.
67. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski P, Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. *J Clin Pharmacol* 1995;35:410-19.
68. Troy SM, Parker VD, Hicks DR, Boudino D, Chiang ST. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. *J Clin Pharmacol* 1996;36:175-181.
69. Houck C, Knowles J, Sisenwine S. Protein Binding of <sup>14</sup>C-Wy-45,030 in Human, Rat and Dog Plasma and Serum. Wyeth-Ayerst Laboratories GTR-12087, 1985.
70. Peri-Okonny U, Howell S. Protein Binding of Wy-45,233 in Rat, Dog and Human Plasma. Wyeth-Ayerst Laboratories GTR-17425, 1989.
71. Amchin JD, Ereshefsky L, Zarycranski WM. Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan. Proceedings of the 149<sup>th</sup> Annual Meeting of the American Psychiatric Association; May 4-9, 1996; New York, NY. NR362:p. 165.



72. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: *in vitro* inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. *Br J Clin Pharmacol* 1997;43:619-26.
73. Amchin J, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effects of venlafaxine on the pharmacokinetics of alprazolam. *Psychopharmacology Bulletin* 1998;34(2):211-19.
74. Amchin J, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. *J Clin Pharmacol* 1999; 39:252-59.
75. Wiklander B, Danjou P, Rolan P; Tamin SK, Toon S. Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine. *Eur Neuropsychopharmacol* 5(3):310-311 (Abs P-2-106) 1995; 8<sup>th</sup> Congr Eur Coll Neuropsychopharmacol, Venice Sep 30-Oct 4, 1995.
76. Fruncillo R. An open-label, multiple-dose drug interaction study to assess the effects of a therapeutic regimen of venlafaxine on CYP2C9 metabolism of tolbutamide: final report (Protocol no. 0600A1-118-US). Wyeth Laboratories CSR-31542 (Synopsis), 2001.
77. Ermer JC, Howell SR, Pruch JM. A <sup>14</sup>C-Labeled metabolic disposition study of an antidepressant (Venlafaxine; Wy-45,030) in healthy volunteers: Final report (Protocol 600A-109-US). Wyeth Ayerst GMR-17400, 1989.
78. Dawson LA, McGonigle P. Effects of acute treatment with Wy-45233, WAY-120197 and WAY-120198 on brain levels of serotonin and norepinephrine in rat cortex (Protocol no.: 776). Wyeth-Ayerst Research. RPT-43824, 2002.
79. Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolizers of debrisoquine. *Eur J Clin Pharmacol*. 2003; 59: 401-406.
80. Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolizers of debrisoquine. *Eur J Clin Pharmacol*. 2003; 59: 401-406.
81. PF-00345408 - Venlafaxine\_2.5 Clinical Overview Venlafaxine CDS Revision\_False Positive Drug Screen\_2012.
82. Warner L. Justification document – Neonatal Discontinuation Effects.
83. Justification Document: Venlafaxine: Neonatal respiratory support or prolongation of hospitalization following transplacental exposure.
84. Haddad PM. Antidepressant Discontinuation syndromes: Clinical relevance. Prevention and management. *Drug Safety* 2001; 24(3):183-197.



85. Hite M. Wy-45,030 HCl\* segment III study in rats. Wyeth-Ayerst Research GTR-16269, 1988.
86. Illett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. *Br J Clin Pharmacol* 1998;45:459-62.
87. Fabre LF, Putman HP. An ascending single-dose tolerance study of Wy-45,030, a bicyclic antidepressant, in healthy men. *Curr Ther Res* 1987;42:901-9.
88. Saletu B, Grünberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping psychometry and psychophysiology. *Br J Clin Pharmacol* 1992;33(6):589-601.
89. Semlitsch HV, Anderer P, Saletu B, Binder GA, Decker KA. Acute effects of the novel anti-depressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjects. *Inter Clin Psychopharmacol* 1993; 8:155-66.
91. Justification Document: Justification for a safety labeling decision for venlafaxine: Chills.
92. Justification Document: Justification for a safety labeling decision for venlafaxine: Angioedema.
93. Justification Document: Justification for a safety labeling decision for venlafaxine: Palpitations.
94. Popik SR: Justification document – QT prolongation, *Torsade de pointes*, Ventricular tachycardia, Ventricular fibrillation.
95. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. *J Clin Psychiatry* 1999; 60(12):857-860.
96. Justification Document: Venlafaxine: Diarrhea.
97. Justification Document: Venlafaxine: Reporting rate of diarrhea.
98. Justification Document: Venlafaxine HCL: Pancreatitis.
99. Justification Document: Venlafaxine: Reporting rate of pancreatitis.
100. Popik, SR: Justification Document – Thrombocytopenia.
101. Justification Document: Venlafaxine: Reporting rate of blood dyscrasias.
102. Offutt, L: Justification document - Agranulocytosis.
103. Offutt, L: Justification document - Aplastic Anemia and Pancytopenia.



104. Offutt, L: Justification document - Neutropenia.
105. Data on file, Supportive documentation for cholesterol changes, February 8, 2000, Wyeth-Ayerst Laboratories.
106. Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis [Letter]. Ann Intern Med. 1999; 130:944.
107. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis [Letter]. Ann Intern Med. 2000; 132:417.
108. Warner L. Justification document – Hepatitis.
109. Popik, SR: Justification document – Hepatitis.
110. Popik, SR: Justification document – Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).
111. Justification Document: Venlafaxine HCL: Prolactin increased.
112. Justification Document: Venlafaxine: Reporting rate of prolactin increased.
113. Justification Document: Venlafaxine HCL: Rhabdomyolysis.
114. Justification Document: Venlafaxine: Reporting rate of rhabdomyolysis.
115. Justification Document: Justification for a safety labeling decision for venlafaxine: Headache.
116. Justification Document: Justification for a safety labeling decision for venlafaxine: Confusion.
117. Justification Document: Justification for a safety labeling decision for venlafaxine: Depersonalization.
118. Justification Document: Venlafaxine HCL: Adverse Reaction: Agitation.
119. Justification Document: Venlafaxine: Frequency of agitation.
120. Justification Document: Justification for a safety labeling decision for venlafaxine: Impaired coordination and balance.
121. Justification Document: Justification for a safety labeling decision for Akathisia.
122. Popik, SR: Justification document – Serotonergic Syndrome.
123. Justification document: Venlafaxine HCL: Adverse Reaction: Delirium.
124. Justification Document: Venlafaxine: Reporting rate of delirium.

According to CDS V 3 dated; 09 June 2021; Supersedes CDS V 3 dated; 10 July 2019



125. Justification Document: Venlafaxine HCL: Extrapyramidal reactions (including dystonia and dyskinesia).
126. Justification Document: Venlafaxine: Reporting rate of extrapyramidal reactions (including dystonia and dyskinesia).
127. Justification Document: Venlafaxine: Reporting rate of tardive dyskinesia.
128. Justification Document: Venlafaxine Hydrochloride: Adverse Reaction: Pulmonary Eosinophilia.
129. Justification Document: Venlafaxine: Reporting rate of pulmonary eosinophilia.
130. Contento R: Justification document – Night Sweats.
131. Contento R: Justification document – Alopecia.
132. Warner L. Justification document – Erythema multiforme.
133. Warner L. Justification document – Stevens-Johnson syndrome.
134. Justification Document: Venlafaxine: Pruritus.
135. Justification Document: Venlafaxine: Reporting rate of pruritus.
136. Justification document: Venlafaxine Hydrochloride: Urticaria
137. Justification for a safety labeling decision for venlafaxine: Toxic epidermal necrolysis.
138. Justification Document: Venlafaxine HCL: Tinnitus.
139. Justification Document: Venlafaxine: Frequency of tinnitus.
140. Justification Document: Justification for a safety labeling decision for venlafaxine: Menstrual disorders.
141. Justification Document: Justification for a safety labeling decision for venlafaxine: Urinary frequency increased and urinary incontinence.
142. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. J Clin Psychopharmacol 1996;16(3) Suppl 2:54S-61S.
143. Justification Document: Venlafaxine HCL: Seizures with Discontinuation.
144. Justification Document: Justification for a safety labeling decision for venlafaxine: Flu-like symptoms.



145. Justification Document: Venlafaxine HCL: Tinnitus with venlafaxine HCL use and with venlafaxine HCL discontinuation.
146. Justification for a safety labeling decision for venlafaxine hydrochloride: Tremor in withdrawal/discontinuation.
147. Justification Document: Justification for a safety labeling decision for venlafaxine – Discontinuation symptoms.
148. Germain, J, Mannion J, White C, Hackett D. Double-blind, placebo-controlled, parallel-group, fixed-dose study of venlafaxine extended release and diazepam followed by a randomized, placebo-controlled, flexible-dose evaluation of relapse prevention and prophylaxis in outpatients with generalized anxiety disorder: Final report (Protocol No. 0600B2-377-EU). Wyeth-Ayerst Research. GMR-31785, 1998.
149. Parks V, White C, Hackett D. A double-blind, placebo-controlled, parallel-group, dose-ranging study of venlafaxine extended-release capsules in outpatients with generalized anxiety disorder: Final report (Protocol No.0600B2-378-EU). GMR-31786, 1998.
150. Justification Document: Venlafaxine HCL: Hostility and Suicide Related Adverse Events.
151. Justification Document: Venlafaxine HCL: Adverse reactions-Pediatric patients, including: decreased appetite, weight loss, increased blood pressure, increased serum cholesterol, abdominal pain, dyspepsia, myalgia, agitation, suicidal ideation, hostility, ecchymosis, epistaxis.
152. Banham NDG. Fatal venlafaxine overdose. Medical J Aust 1998;169(8):445-8.
153. Parsons AT, Anthony RM, Meeker JE. Two fatal cases of venlafaxine poisoning. J Anal Toxicol 1996;20(4):26-8.
154. Dahl B, Crouch BI, Rollins D. Death from venlafaxine overdose (Effexor®). J Toxicol Clin Toxicol 1996;34(5) Suppl 12:557.
155. Litovitz TL, Smilkstein M, Felberg L, Klein-Schwartz W, Berlin R, Morgan JL. 1996 Annual report of the american association of poison control centers toxic exposure surveillance system. Am J Emerg Med 1997;15(5):447, 468.
156. Justification Document: Venlafaxine HCL: Overdosage: Most commonly reported Adverse Events.
157. Shah R, Uren Z, Baker A, Majeed A. Deaths from antidepressants in England and Wales 1993-1997: analysis of a new national database. Psychological Medicine 2001; 31:1203-1210.
158. Cheetah S, Schifano F, Oyefeso A, Webb L, Ghodse H. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. British Journal of Psychiatry 2004;184:41-47.



159. Buckley NA, McManus PR. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. *BMJ* 2002; 325:1332–1333.
160. Morgan O, Griffiths C, Baker A, Majeed A. Fatal toxicity of antidepressants in England and Wales, 1993–2002. *Health Statistics Quarterly* 2004; 23:18–24.
161. Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. *Pharmacoepidemiology and Drug Safety* 2005;14:367-372.
162. Rubino A, Roskell N, Tennis P, Andrews E. Risk of suicide in patients treated with venlafaxine compared to fluoxetine, citalopram, and dothiepin. A longitudinal analysis of the GPRD. RTI-HS Project no. B0578. January 20, 2006.
163. Fireman B, Lee J, Hunkler E. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Final report February 23, 2006.
164. Haskins JT, Moyer JA, Muth EA, Ernest B. DMI, WY-45,030, WY-45,881 and citalopram inhibit locus coeruleus neuronal activity. *Eur J Pharmacol* 1985; 115:139-46.
165. Bill DJ, Fletcher A. Chronic administration of the new antidepressant, venlafaxine, is anxiolytic in the mouse light:dark box model of anxiety. *Can J Physiol Pharmacol* 1994; 17 Suppl 1:440.
166. Morris H, Boast C, Moyer JA, Muth EA. Venlafaxine and idebenone attenuate scopolamine-impaired radial-arm maze deficits in rats. Wyeth-Ayerst Laboratories GTR-20531, 1992.
171. Feighner J, Entsuah A, McPherson M. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. *J Affect Disord* 1998; 47:55-62.
172. Cunningham LA, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. *Ann Clin Psychiatry* 1997;9(3):157-64.
173. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended-release (XR) in outpatients with major depression. *J Clin Psychiatry* 1997; 58(9):393-8.
174. Hamilton MA. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23:56-62.
175. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; 134:382-9.



176. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW Pub. No. (ADM) 76-338. Rockville, MD: National Institutes of Mental Health, 1976; 217-222.
177. Derivan A, Haskins T, Rudolph R, Pallay A, Aguiar L, for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD). Proceedings of the American Psychiatric Association Annual Meeting; June 1998; Toronto, Ontario.
178. Davidson J, DuPont R, Hedges D, Haskins T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. *J Clin Psychiatry* 1999;60:528-535.
179. Jokela H, Karkkainen J, Pekkarinen H, et al. A double-blind, placebo-controlled, parallel-group, dose-ranging study of venlafaxine extended-release capsules in outpatients with general anxiety disorder: final report (Protocol 0600B2-378-EU). Wyeth-Ayerst Laboratories GMR-31786, 1997.
180. Hackett D, Parks V, Salinas E, for the Venlafaxine XR 378 Study Group. A 6-month evaluation of 3 dose levels of venlafaxine extended-release in non-depressed outpatients with generalized anxiety disorder. Proceeding from the Annual Meeting of the Anxiety Disorders Association of America; March 26, 1999; San Diego, CA.
181. Cunningham L, Hartford J, Londborg P, Munjack D, Patterson W, Smith W, et al. A six-month double-blind, placebo-controlled, parallel-group, comparison of venlafaxine extended release capsules and placebo in outpatients with generalized anxiety disorder: final report (Protocol 0600B2-218-US). Wyeth-Ayerst Laboratories GMR-32976, 1997.
182. Haskins JT, Rudolph R, Aguiar L, Entsuah R, Salinas E, for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder. Proceedings from the Annual Meeting of the Anxiety Disorders Association of America; March 26, 1999; San Diego, CA.
183. Howell SR, Husbands GEM, Scatina JA, Sisenwine SF. Metabolic disposition of <sup>14</sup>C-venlafaxine in mouse, rat, dog, rhesus monkey and man. *Xenobiotica* 1993;23(4):349-59.
184. Patat A, Troy SM, Burke J, et al. The absolute bioavailability and EEG effects of conventional formulation and extended release venlafaxine in healthy subjects. *J Clin Pharmacol* 1998; 38:256-67.
185. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. *J Clin Pharmacol* 1992; 32:716-24.
186. Troy S, Dilea C, Martin P, Rosen A, Fruncillo R, Chiang S. Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers. *Curr Ther Res* 1997; 58(8):492-503.



187. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation *in vitro* is catalysed by CYP2D6. *Br J Pharmacol* 1996; 41:149-56.
188. Fogelman S, Schmider J, Greenblatt DJ, Shader RI. Metabolism of venlafaxine: the role of P450 isoforms. *J Clin Pharmacol* 1995; 35:936.
189. Ball SE, Scatina JA, Sisenwine SF. Venlafaxine: Stereoselective metabolism and interactions with cytochromes P450 2D6 and 3A3/4 in Human liver mincrosomes-*in vitro* studies by Dr. Sellers (Protocol 600-A). Wyeth-Ayerst Research GTR-23916, 2003.
190. Blouin R, Fruncillo R. An open-label study of pharmacokinetics of venlafaxine in extensive and poor metabolizers of dextromethorphan: final report (Protocol 600A-131-US). Wyeth-Ayerst Laboratories GMR-26711, 1995.
191. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. *J Clin Pharmacol* 1995; 35:404-9.
192. Troy S, Dilea C, Martin P, Leister C, Fruncillo R, Chiang S. Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers. *Curr Ther Res* 1997; 58(8):504-14.
193. Troy S, Reed H, Conrad K. The effect of food on the bioavailability of orally administered venlafaxine HCl: final report (Protocol 600A-113-US). Wyeth-Ayerst Laboratories GMR-18470, 1989.
194. Blum R and Lasseter K. A randomized, open-label, crossover study of the pharmacokinetics of intravenous and oral venlafaxine in subjects with hepatic impairment and healthy control volunteers: final report (protocol 0600A1-140-US). Wyeth-Ayerst CSR-38553, 2002
195. Jim K, Entsuah AR, Upton GV. Double-blind, placebo-controlled, parallel-group dosage-determination study of low doses of venlafaxine in depressed patients: interim report (Protocol 600A-313-US EXT). Wyeth-Ayerst Laboratories GMR-20520, 1991.
196. Bendas CM, Entsuah R, Upton GV. An open-label evaluation of the long-term safety and clinical acceptability of oral venlafaxine (Wy-45,030) tablets in depressed outpatients: interim report (Protocol 600A-312-US). Wyeth-Ayerst Laboratories GMR-20525, 1993.
197. Wetzel J. Wy-45,030 HCl eighteen month oral (intubation) carcinogenicity study – mice (Protocol 600A2-88515). Wyeth-Ayerst Laboratories GTR-17646, 1990.
198. Wetzel J. Wy-45,030 HCl two year oral (intubation) toxicity and oncogenicity study – rats (Protocol 600A2-88516). Wyeth-Ayerst Laboratories GTR-18320, 1990.
199. Peters, L. Evaluation of Wy-45,233\* by the salmonella/microsome mutagenicity test (Ames test). Wyeth-Ayerst Laboratories GTR-14871, 1987.
200. Loveday K, Kim N, Little A. CHO/HGPRT *in vitro* mammalian cell mutation assay with Wy-45,233 base. Wyeth-Ayerst Laboratories GTR-17647, 1990.



201. 2.4 Nonclinical Overview for Desvenlafaxine: 2014-08 PF-00345408-Section 5.3- to support update for mutagenicity.
202. Stadnicki S. Evaluation of Wy-45,030 HCl and Wy-45,233 base in the BALB/c-3T3 cell transformation assay (Protocol 600A2-88520). Wyeth-Ayerst Laboratories GTR-16898, 1989.
203. Stadnicki S. Wy-45,233C *in vitro* chromosomal aberration assay (Protocol 600A2-88521). Wyeth-Ayerst Laboratories GTR-15984, 1989.
204. Stadnicki S. *In vivo* chromosomal aberration assay in rats with Wy-45,233 base (Protocol 600A2-88523). Wyeth-Ayerst Laboratories GTR-17770, 1990.
205. Ryan E. A Fertility and General Reproductive Performance Study in Rats with Wy-45,030\* HCl (study code no. 154). Wyeth-Ayerst GTR-13878, 1987.
206. Justification Document: Venlafaxine HCl: Additional Wording to the “Impairment of Fertility” section of the CDS
207. Justification Document: Venlafaxine HCl: Infertility
208. Ryan EL. Wy-45,030\* HCl teratology study in rats study code no 135. Wyeth GTR 13809, 1987.
209. Andersen J, Cook MJ. Wy-45030: Effect on pregnancy and foetal development in the dutch rabbit 45030/001 and 45030/002. Wyeth (U.K.) GTR 12657, 1986.
210. Clinical Overview: Venlafaxine HCl: Dyspnoea
211. Venlafaxine\_2012\_Clinical Overview Nonrenewal\_CDS update for CDS\_USPI\_SPC\_Health Canada Class Labeling
212. Clinical Overview: Venlafaxine and QTc Prolongation/*Torsades de Pointes*, March 2013
213. Clinical Overview: Venlafaxine (CDS update Interstitial lung disease), May 2015.
214. Frequency Justification Document: Venlafaxine (CDS update ADR Frequency), September 2018.
215. Clinical Overview: Venlafaxine (CDS update to section 5.1), June 2017.
216. Clinical Overview: Venlafaxine (CDS update to section 4.4 and section 4.5), July 2017.
217. 2.5 Clinical Overview for Venlafaxine CDS Updates, Updates to section 4.6, August 2018.
218. 2.5 Clinical Overview for Venlafaxine CDS Updates, Updates to section 4.8 – Addition of Stress Cardiomyopathy, September 2018.



219. 2.5 Clinical Overview to Support the Updates of Discontinuation Effects to Sections 2, 4.2, 4.4, and 4.8 of the Venlafaxine Core Data Sheet, July 2019.
220. 2.5 Clinical Overview to Support the Update of Sexual Dysfunction after Discontinuation to Section 4.4 of the Venlafaxine Core Data Sheet, July 2019.
221. 2.5 Clinical Overview, To Support the Updates to Section 4.4 Special Warnings and Precautions to Use and Section 4.5 Interaction With Other Medicinal Products and Other Forms of Interaction of the Core Data Sheet, May 2021.